ReviewMolecular cancer2026
Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
T-cell bispecific antibodies (TCBs), a specialized subclass of bispecific antibodies (BsAbs), are engineered to simultaneously engage T cells and tumor cells by binding two distinct antigens-or two epitopes on a single antigen-thereby redirecting cytotoxic T lymphocytes to eliminate malignant cells. These agents enhance anti-tumor immunity through dual mechanisms: direct activation of T cell receptor (TCR)-mediated signaling and modulation of T cell function via immune checkpoint (ICP) pathways. Clinically, TCBs have demonstrated transformative efficacy, particularly in hematologic cancers, heralding a new era in tumor immunotherapy. Despite their therapeutic promise, widespread clinical adoption of TCBs is impeded by significant challenges-including severe immune-related toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as resistance conferred by the immunosuppressive tumor microenvironment (TME). This review provides a comprehensive analysis of TCBs, encompassing their molecular design, mechanisms of action, and clinical performance across oncology indications. We systematically compare current TCB platforms with respect to therapeutic strategy, structural format selection, safety profiles, and clinical outcomes. Additionally, we critically evaluate the major translational hurdles facing TCB-based therapies and explore emerging solutions-including the development of novel format antibodies, rational combination regimens with immune checkpoint inhibitors or other immunomodulators, the application of artificial intelligence (AI) in de novo antibody design, and antibody drug conjugates (ADCs). In summary, this review not only highlights the current landscape and limitations of TCBs but also outlines actionable strategies to overcome existing barriers-serving as a valuable resource for researchers, clinicians, and biopharmaceutical developers striving to advance the next generation of T-cell redirecting therapies into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.